Israeli Ag Tech Delegation Visits St. Louis
The BIRD Foundation has fostered partnerships between Israeli technology startups and companies and U.S. corporations since it was founded in 1977.
Now the group has brought its first delegation to St. Louis.
Twelve Israeli ag tech companies are in town for a two-day visit to make pitches to investors and meet individually with Monsanto, KWS and others.
Limor Nakar-Vincent, the BIRD Foundation’s deputy executive director for business development, said there’s an emphasis on collaboration in St. Louis’ bio-science and ag ecosystem.
“It’s very unique to find such strong local commitment that truly believes in a win-win situation for both helping foreign companies come over and establish roots and vice versa,” she said.
Click here to view the list of companies
March 6, 2017
St. Louis Public Radio
Marrone Bio Innovations and Groundwork BioAg Bio-stacked Microbial Seed Treatments Result in Increased Corn and Soybean Yields
Treatments show reduction of corn rootworm and nematodes
DAVIS, Calif. and MOSHAV MAZOR, Israel, Feb. 13, 2017 — Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI) and Groundwork BioAg, Ltd. (Groundwork) today announced successful seed treatment field trials of the world’s first all-biological comprehensive seed treatment. The treatments tested in corn and soybeans contained a mycorrhizal inoculant from Groundwork, as well as a bioinsecticide, a bionematicide, and a biofungicide from MBI.
The Biological Stack Seed Treatment (BSST) is comprised of two insecticidal/nematicidal bacteria, one biostimulant/fungicidal bacterium and mycorrhizal fungi. Together, these synergistic microorganisms can provide a wide scope of benefits to growers: crop yield increases, resilience under abiotic stress conditions, reduction of fertilizer requirements (especially phosphorus), and resistance to soil-dwelling pests and plant diseases. In fact, we believe BSST constitutes the first all-biological seed treatment able to effectively provide all of these benefits without synthetic pesticides.
Feb. 13, 2017
Gene Editing Institute at Christiana Care Health System partners with NovellusDx in BIRD Foundation Grant
The Gene Editing Institute of Christiana Care Health System’s Helen F. Graham Cancer Center & Research Institute has been awarded a $900,000 grant from the U.S.-Israel Binational Industrial Research and Development (BIRD) Foundation, in partnership with Israeli biotechnology company NovellusDx.
The Gene Editing Institute and NovellusDx will use the grant money to research a new series of state-of-the-art gene editing technologies that help identify the genetic mechanism responsible for both the onset and progression of many types of cancer. The two organizations are collaborating on a licensing agreement to commercialize the gene editing technologies that result from the research.
“Thanks to this generous BIRD Foundation grant, this partnership promises to be a catalyst that will speed progress in personalized medicine for many forms of cancer, accelerating the path to prevention, diagnosis, treatment, and ultimately, to a cure of cancer,” said Nicholas J. Petrelli, M.D., the Bank of America endowed medical director of the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System.
Jan. 30, 2017